In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results For an adult with type 2 diabetes mellitus who requires substantial weight loss, what are the recommended use, dosing, regulatory approval status, and contraindications of tirzepatide compared with cagrilintide, and what alternative Dinner is served #tirzepatide #cagrilintide #summer #gym #fyp #bodypos TikTok CagriSema misses noninferiority vs tirzepatide in REDEFINE 4; Novo Nordisk shares fall 15% iPharmaCenter